As per MRFR analysis, the South Korea Ophthalmic Drugs and Devices Market Size was estimated at 1.15 (USD Billion) in 2023. This market is expected to grow from 1.25 (USD Billion) in 2024 to 7.2 (USD Billion) by 2035. The South Korea Ophthalmic Drugs and Devices Market CAGR (growth rate) is expected to be around 17.254% during the forecast period (2025 - 2035).
The South Korea Ophthalmic Drugs and Devices Market is showing significant shifts as a result of an older demographic and the growing occurrence of eye-related illnesses. The government is aware of improving healthcare services and is, therefore, promoting the development of ophthalmic care and technology.
There is an upsurge of research initiatives focusing on creating new drugs and devices suitable for the South Korean population which addresses their specific needs. Furthermore, the growth of digital health and telemedicine innovations are transforming eye care services in ophthalmology by offering patients easier access to consultations and greatly enhancing the accessibility of eye care.
The expansion of opportunities in the ophthalmic sector in South Korea is fueled by local firms looking to partner with foreigners for easier transfer of knowledge and quicker innovation. Companies are now actively investing in advanced technologies because there is a high demand for sophisticated diagnostic devices and surgical instruments.
With the new policies of the South Korean government aiming to increase the level of healthcare concerning chronic eye diseases, new product lines specific to glaucoma treatment and retinal care are set to emerge. More focal attention is given to personalized medicine in ophthalmology, and the care patients receive is shifting to more individualized treatment plans.
Moreover, their expansion comes with the help of South Korean e-commerce. The shift in purchasing patterns of patients looking for ophthalmic medicines towards online pharmacies shows that traditional pharmacies need to rethink their business approach. All of these changes show that there is strong technological growth and innovative shifts occurring that are actively working to satisfy the needs of the citizens of South Korea.
The South Korea Ophthalmic Drugs and Devices Market is experiencing significant growth driven by the increasing demand for advanced treatment options for various eye disorders. As per the Ministry of Health and Welfare, the prevalence of eye diseases such as cataracts and glaucoma is expected to rise, with projections indicating that cataract surgeries alone will reach over 600,000 procedures annually by 2025.
This surge is compelling pharmaceutical companies and medical device manufacturers like Samsung Medical Center and Hanmi Pharmaceutical to innovate and expand their product lines in the ophthalmic sector. Furthermore, advancements in technology such as telemedicine and minimally invasive surgical techniques are creating opportunities for rapid market growth, driving substantial investments in Research and Development by leading firms in the region. This trend indicates a robust opportunity landscape, aligning with the country's focus on enhancing healthcare services and improving patient outcomes in ophthalmology.
The aging population in South Korea is a pivotal driver of the growth in the South Korea Ophthalmic Drugs and Devices Market. According to Statistics Korea, the proportion of individuals aged over 65 is projected to reach 24% by 2025, resulting in a higher incidence of age-related eye diseases such as macular degeneration and diabetic retinopathy.
This demographic shift encourages healthcare providers and governments to advocate for enhanced ophthalmic care and comprehensive management strategies. The Eye Care Center established by Korea National Hospital is an exemplary initiative targeting these growing needs, enhancing access to specialized treatments and innovation in ophthalmic devices.
Rapid technological advancements in ophthalmic devices are significantly contributing to the South Korea Ophthalmic Drugs and Devices Market's expansion. The introduction of artificial intelligence in diagnostic equipment and the development of smart wearable eye devices have revolutionized patient management and treatment.
Companies like LG Electronics are leading in smart lens technology, enhancing vision correction and comfort. The increasing incorporation of digital health solutions in ophthalmology is projected to provide improved outcomes for patients while optimizing operational efficiency for healthcare providers. This trend is further supported by South Korea's strong emphasis on innovative technologies in healthcare as part of its 'Digital New Deal' initiative, leading to increased investments in medical technology.
The South Korean government plays a crucial role in the growth of the South Korea Ophthalmic Drugs and Devices Market through various healthcare reforms and support initiatives. Policies aimed at increasing healthcare accessibility and affordability are fostering a conducive environment for market players.
For instance, the shift toward universal health coverage is providing a wider population with access to ophthalmic services. The government has initiated programs to subsidize costs for eye care treatments and innovative devices, encouraging investments from both domestic and international companies. This supportive regulatory environment is essential for enhancing competition and innovation in the ophthalmic sector, thereby driving market growth.
The South Korea Ophthalmic Drugs and Devices Market is characterized by a diverse array of products that cater to various ocular conditions, underscoring the increasing awareness and focus on eye health in the region. With the national emphasis on improving healthcare access and quality, the market has witnessed a significant shift towards innovative ophthalmic solutions.
The product segment can be broadly divided into drugs and devices, each playing a crucial role in addressing eye diseases. Drugs, including anti-inflammatories, glaucoma medications, and anti-VEGF therapies, are essential for managing both chronic and acute ophthalmic conditions, thereby promoting patient compliance and enhancing treatment outcomes.
Meanwhile, devices such as diagnostic equipment and surgical instruments are vital in the detection, monitoring, and intervention of ocular disorders. The growing prevalence of vision-related issues, including age-related macular degeneration and diabetic retinopathy, is driving demand for these products, further supported by South Korea's aging population.
Notably, advances in medical technology and the integration of artificial intelligence in ophthalmic devices are enhancing diagnostic accuracy and treatment efficacy, presenting vast opportunities for market expansion. The government has also implemented various health initiatives aimed at increasing public awareness about the importance of regular eye examinations, which complements market growth.
Furthermore, there is a noticeable trend towards minimally invasive surgical methods, which is propelling the development and adoption of innovative devices designed for better surgical precision and quicker recovery times. The South Korea Ophthalmic Drugs and Devices Market statistics reflect an ongoing commitment to improving eye health and treatment methodologies through research and development efforts, ensuring that both drugs and devices address the evolving needs of the population effectively. As healthcare professionals continue to seek effective treatment solutions, this segment is expected to adapt and evolve, establishing a significant foundation for future innovations in the industry.
The Treatment segment of the South Korea Ophthalmic Drugs and Devices Market plays a crucial role in addressing various eye-related ailments, reflecting the increasing demand for effective therapeutic solutions. Eye infections have been a prominent area of concern, with a rising prevalence due to factors such as environmental pollution and lifestyle changes, leading to a significant focus on developing targeted therapies.
Allergic conjunctivitis remains a common issue in South Korea, driven by high pollen levels and urban pollution, highlighting the need for advanced antihistamines and anti-inflammatory treatments. The dry eyes syndrome is notably significant, with a large portion of the population experiencing symptoms primarily due to prolonged screen exposure, prompting innovation in artificial tears and moisture-retaining solutions.
Additionally, the segment addressing red eyes and inflammation is essential for the management of ocular conditions caused by both environmental and chronic factors. The introduction of new treatments in other unspecified categories also plays a role in expanding the portfolio of options available for patients. Overall, the dynamic landscape of the Treatment segment reflects the ongoing efforts to enhance the quality of care in the South Korea Ophthalmic Drugs and Devices Market, driven by advancing Research and Development and a growing awareness of eye health among the population.
The South Korea Ophthalmic Drugs and Devices Market is characterized by a blend of advanced technology, significant research and development efforts, and a keen focus on patient-centric solutions. The competitive landscape is shaped by both domestic and international players, each vying for market share through innovation and strategic partnerships.
A growing aging population, alongside an increase in eye-related conditions, is driving demand for a wide range of ophthalmic products including therapeutic agents, surgical devices, and diagnostic tools. As the market evolves, companies are tapping into cutting-edge advancements such as biologics and minimally invasive surgeries to improve patient outcomes and capture a more considerable foothold in this lucrative sector.
Amgen has established a robust presence in the South Korea Ophthalmic Drugs and Devices Market, underscoring its commitment to enhancing eye health through its innovative product offerings. The company stands out due to its strong research foundation, which emphasizes the development of biologic drugs aimed at treating major ocular diseases.
With a strategic focus on local partnerships and a deep understanding of regional healthcare needs, Amgen has successfully positioned itself as a leader by tailoring its therapies to better align with South Korean market demands. Furthermore, the company leverages its global expertise and technological capabilities to enhance its product effectiveness and accessibility, strengthening its footprint in this competitive landscape.
Sun Pharmaceutical is another key player in the South Korea Ophthalmic Drugs and Devices Market, known for a diverse portfolio of ophthalmic products that address both surgical and therapeutic needs. The company's strengths lie in its innovative R&D facilities and a strong distribution network that ensures efficiency and accessibility of its products in the region.
Sun Pharmaceutical is particularly recognized for its injectable formulations and advanced surgical solutions, which have gained traction among healthcare professionals and patients alike. Additionally, the company is actively pursuing strategic mergers and acquisitions to enhance its market presence further, boosting its capabilities to deliver cost-effective healthcare solutions tailored to the South Korean market. Through its commitment to quality and innovation, Sun Pharmaceutical continues to solidify its position as a trusted provider of ophthalmic drugs and devices in South Korea.
The South Korea Ophthalmic Drugs and Devices Market has recently experienced notable developments, with a significant focus on innovation and market growth. Companies like Alcon and Novartis are actively expanding their product lines, particularly in minimally invasive surgical devices, which have gained traction among healthcare professionals.
Amgen and Ocular Therapeutix are also investing heavily in Research and Development for novel therapeutic solutions in treating eye conditions. In September 2023, Johnson and Johnson announced enhancements in their surgical instrument technology aimed at improving patient outcomes. Additionally, in July 2023, Merck acquired a smaller firm specializing in retinal therapies, further solidifying its presence in this competitive market.
The current valuation of the South Korean ophthalmic sector has seen an upward trend, attributed to aging populations and increasing prevalence of eye diseases, compelling major players to increase their strategic partnerships and investments. Aerie Pharmaceuticals and Santen Pharmaceutical are also ramping up their activities in the field, responding to the growing demand for advanced eye care solutions. The solid regulatory framework in South Korea continues to foster a vibrant market environment conducive for these companies to thrive and innovate.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 1.15(USD Billion) |
| MARKET SIZE 2024 | 1.25(USD Billion) |
| MARKET SIZE 2035 | 7.2(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 17.254% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Amgen, Sun Pharmaceutical, Alcon, Merck, Ocular Therapeutix, Johnson & Johnson, Glaukos, MediEye, Bausch Health, Aerie Pharmaceuticals, AbbVie, Hugel, Novartis, Santen Pharmaceutical |
| SEGMENTS COVERED | Product, Treatment |
| KEY MARKET OPPORTUNITIES | Telemedicine for eye care, Growing aging population, Increased prevalence of eye diseases, Innovation in minimally invasive procedures, Expanding reimbursement policies for eye treatments |
| KEY MARKET DYNAMICS | Aging population increase, Rising prevalence of eye diseases, Advanced technological innovations, Growing healthcare expenditure, Increased demand for vision correction |
| COUNTRIES COVERED | South Korea |
Frequently Asked Questions (FAQ) :
The projected market size of the South Korea Ophthalmic Drugs and Devices Market is 1.25 USD Billion in 2024.
The estimated market value of the South Korea Ophthalmic Drugs and Devices Market is expected to reach 7.2 USD Billion by 2035.
The expected CAGR for the South Korea Ophthalmic Drugs and Devices Market from 2025 to 2035 is 17.254%.
The South Korea Ophthalmic Drugs and Devices Market is segmented into two main product types: Drugs and Devices.
The market value of Ophthalmic Drugs in South Korea is valued at 0.75 USD Billion in 2024.
The forecasted market value of Ophthalmic Devices in South Korea is expected to reach 2.95 USD Billion by 2035.
Key players in the South Korea Ophthalmic Drugs and Devices Market include Amgen, Sun Pharmaceutical, Alcon, Merck, and Johnson & Johnson.
Growth drivers for the market include increasing prevalence of eye diseases and technological advancements in ophthalmic devices.
Emerging trends in the market include the development of innovative drug delivery systems and personalized medicine for ocular conditions.
The South Korea Ophthalmic Drugs and Devices Market is positioned for substantial growth, making it a competitive region compared to others in the Asia-Pacific.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
